Fermenta Biotech Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 29, 2025, 1:26 pm

Quick Insight

Fermenta Biotech Ltd, operating in the pharmaceutical industry with a share price of 327 and a market capitalization of 963 Cr., shows promising fundamentals with a P/E ratio of 9.22 and robust returns on equity and capital at 24.9% and 23.0% respectively. The company's operational efficiency is evident with an operating profit margin of 21%, while its net profit stands at 76 Cr. However, the absence of significant institutional ownership raises questions about market perception. With healthy reserves of 348 Cr. and manageable borrowings of ₹115 Cr., Fermenta Biotech's current ratio of 8.57x indicates a strong financial position, yet a closer look at its working capital cycle of 189 days may warrant attention for potential optimization. The price-to-book value of 2.23x suggests the stock is trading above its book value, reflecting investor confidence in future growth prospects. Overall, despite sound financial metrics, investor sentiment and working capital efficiency are key areas for monitoring to maximize shareholder value.

Competitors of Fermenta Biotech Ltd

All Competitor Stocks of Fermenta Biotech Ltd

Quarterly Result

Last Updated: August 19, 2025, 3:45 pm

Below is a detailed analysis of the quarterly data for Fermenta Biotech Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 136.00 Cr.. The value appears to be declining and may need further review. It has decreased from 140.00 Cr. (Mar 2025) to 136.00 Cr., marking a decrease of 4.00 Cr..
• For Expenses, as of Jun 2025, the value is 108.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 103.00 Cr. (Mar 2025) to 108.00 Cr., marking an increase of 5.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 28.00 Cr.. The value appears to be declining and may need further review. It has decreased from 37.00 Cr. (Mar 2025) to 28.00 Cr., marking a decrease of 9.00 Cr..
• For OPM %, as of Jun 2025, the value is 21.00%. The value appears to be declining and may need further review. It has decreased from 26.00% (Mar 2025) to 21.00%, marking a decrease of 5.00%.
• For Other Income, as of Jun 2025, the value is 9.00 Cr.. The value appears strong and on an upward trend. It has increased from 4.00 Cr. (Mar 2025) to 9.00 Cr., marking an increase of 5.00 Cr..
• For Interest, as of Jun 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.00 Cr..
• For Depreciation, as of Jun 2025, the value is 6.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 6.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 28.00 Cr.. The value appears to be declining and may need further review. It has decreased from 32.00 Cr. (Mar 2025) to 28.00 Cr., marking a decrease of 4.00 Cr..
• For Tax %, as of Jun 2025, the value is 23.00%. The value appears to be increasing, which may not be favorable. It has increased from -4.00% (Mar 2025) to 23.00%, marking an increase of 27.00%.
• For Net Profit, as of Jun 2025, the value is 22.00 Cr.. The value appears to be declining and may need further review. It has decreased from 33.00 Cr. (Mar 2025) to 22.00 Cr., marking a decrease of 11.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 7.42. The value appears to be declining and may need further review. It has decreased from 11.68 (Mar 2025) to 7.42, marking a decrease of 4.26.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 1:29 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: July 25, 2025, 1:18 pm

Below is a detailed analysis of the balance sheet data for Fermenta Biotech Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 15.00 Cr.. The value appears strong and on an upward trend. It has increased from 14.00 Cr. (Mar 2024) to 15.00 Cr., marking an increase of 1.00 Cr..
• For Reserves, as of Mar 2025, the value is 348.00 Cr.. The value appears strong and on an upward trend. It has increased from 274.00 Cr. (Mar 2024) to 348.00 Cr., marking an increase of 74.00 Cr..
• For Borrowings, as of Mar 2025, the value is 115.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 139.00 Cr. (Mar 2024) to 115.00 Cr., marking a decrease of 24.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 137.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 120.00 Cr. (Mar 2024) to 137.00 Cr., marking an increase of 17.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 614.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 548.00 Cr. (Mar 2024) to 614.00 Cr., marking an increase of 66.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 227.00 Cr.. The value appears to be declining and may need further review. It has decreased from 269.00 Cr. (Mar 2024) to 227.00 Cr., marking a decrease of 42.00 Cr..
• For CWIP, as of Mar 2025, the value is 16.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Mar 2024) to 16.00 Cr., marking an increase of 14.00 Cr..
• For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Other Assets, as of Mar 2025, the value is 372.00 Cr.. The value appears strong and on an upward trend. It has increased from 277.00 Cr. (Mar 2024) to 372.00 Cr., marking an increase of 95.00 Cr..
• For Total Assets, as of Mar 2025, the value is 614.00 Cr.. The value appears strong and on an upward trend. It has increased from 548.00 Cr. (Mar 2024) to 614.00 Cr., marking an increase of 66.00 Cr..

Notably, the Reserves (348.00 Cr.) exceed the Borrowings (115.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Key Financial Ratios

After reviewing the key financial ratios for Fermenta Biotech Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 26.35. This value is within the healthy range. It has increased from -7.99 (Mar 24) to 26.35, marking an increase of 34.34.
• For Diluted EPS (Rs.), as of Mar 25, the value is 26.35. This value is within the healthy range. It has increased from -7.99 (Mar 24) to 26.35, marking an increase of 34.34.
• For Cash EPS (Rs.), as of Mar 25, the value is 34.50. This value is within the healthy range. It has increased from 0.24 (Mar 24) to 34.50, marking an increase of 34.26.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 122.91. It has increased from 98.76 (Mar 24) to 122.91, marking an increase of 24.15.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 122.91. It has increased from 98.76 (Mar 24) to 122.91, marking an increase of 24.15.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 160.95. It has increased from 116.25 (Mar 24) to 160.95, marking an increase of 44.70.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 41.69. This value is within the healthy range. It has increased from 13.62 (Mar 24) to 41.69, marking an increase of 28.07.
• For PBIT / Share (Rs.), as of Mar 25, the value is 33.39. This value is within the healthy range. It has increased from 5.06 (Mar 24) to 33.39, marking an increase of 28.33.
• For PBT / Share (Rs.), as of Mar 25, the value is 28.53. This value is within the healthy range. It has increased from -3.42 (Mar 24) to 28.53, marking an increase of 31.95.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 26.19. This value is within the healthy range. It has increased from -8.31 (Mar 24) to 26.19, marking an increase of 34.50.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 26.35. This value is within the healthy range. It has increased from -7.99 (Mar 24) to 26.35, marking an increase of 34.34.
• For PBDIT Margin (%), as of Mar 25, the value is 25.90. This value is within the healthy range. It has increased from 11.71 (Mar 24) to 25.90, marking an increase of 14.19.
• For PBIT Margin (%), as of Mar 25, the value is 20.74. This value exceeds the healthy maximum of 20. It has increased from 4.34 (Mar 24) to 20.74, marking an increase of 16.40.
• For PBT Margin (%), as of Mar 25, the value is 17.72. This value is within the healthy range. It has increased from -2.94 (Mar 24) to 17.72, marking an increase of 20.66.
• For Net Profit Margin (%), as of Mar 25, the value is 16.27. This value exceeds the healthy maximum of 10. It has increased from -7.15 (Mar 24) to 16.27, marking an increase of 23.42.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 16.37. This value is within the healthy range. It has increased from -6.86 (Mar 24) to 16.37, marking an increase of 23.23.
• For Return on Networth / Equity (%), as of Mar 25, the value is 21.43. This value is within the healthy range. It has increased from -7.98 (Mar 24) to 21.43, marking an increase of 29.41.
• For Return on Capital Employeed (%), as of Mar 25, the value is 24.19. This value is within the healthy range. It has increased from 3.89 (Mar 24) to 24.19, marking an increase of 20.30.
• For Return On Assets (%), as of Mar 25, the value is 12.50. This value is within the healthy range. It has increased from -4.20 (Mar 24) to 12.50, marking an increase of 16.70.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 0.2. It has decreased from 0.14 (Mar 24) to 0.04, marking a decrease of 0.10.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.30. This value is within the healthy range. It has decreased from 0.45 (Mar 24) to 0.30, marking a decrease of 0.15.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.80. It has increased from 0.56 (Mar 24) to 0.80, marking an increase of 0.24.
• For Current Ratio (X), as of Mar 25, the value is 1.58. This value is within the healthy range. It has increased from 1.40 (Mar 24) to 1.58, marking an increase of 0.18.
• For Quick Ratio (X), as of Mar 25, the value is 0.99. This value is below the healthy minimum of 1. It has increased from 0.89 (Mar 24) to 0.99, marking an increase of 0.10.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.13. This value is below the healthy minimum of 4. It has increased from 0.70 (Mar 24) to 1.13, marking an increase of 0.43.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has increased from -15.65 (Mar 24) to 0.00, marking an increase of 15.65.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 217.49 (Mar 24) to 0.00, marking a decrease of 217.49.
• For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 115.65 (Mar 24) to 0.00, marking a decrease of 115.65.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has increased from -117.49 (Mar 24) to 0.00, marking an increase of 117.49.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 8.57. This value is within the healthy range. It has increased from 2.31 (Mar 24) to 8.57, marking an increase of 6.26.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 6.38. This value is within the healthy range. It has increased from 0.02 (Mar 24) to 6.38, marking an increase of 6.36.
• For Enterprise Value (Cr.), as of Mar 25, the value is 835.62. It has increased from 505.89 (Mar 24) to 835.62, marking an increase of 329.73.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.78. This value is within the healthy range. It has increased from 1.51 (Mar 24) to 1.78, marking an increase of 0.27.
• For EV / EBITDA (X), as of Mar 25, the value is 6.87. This value is within the healthy range. It has decreased from 12.87 (Mar 24) to 6.87, marking a decrease of 6.00.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.70. This value is within the healthy range. It has increased from 1.30 (Mar 24) to 1.70, marking an increase of 0.40.
• For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 115.65 (Mar 24) to 0.00, marking a decrease of 115.65.
• For Price / BV (X), as of Mar 25, the value is 2.23. This value is within the healthy range. It has increased from 1.51 (Mar 24) to 2.23, marking an increase of 0.72.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.70. This value is within the healthy range. It has increased from 1.30 (Mar 24) to 1.70, marking an increase of 0.40.
• For EarningsYield, as of Mar 25, the value is 0.09. This value is below the healthy minimum of 5. It has increased from -0.05 (Mar 24) to 0.09, marking an increase of 0.14.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness